M. Lattanzi

发表

Patterns of Macrolide Resistance Determinants among Community-Acquired Streptococcus pneumoniae Isolates over a 5-Year Period of Decreased Macrolide Susceptibility Rates

G. Rossolini, P. Oster, A. Zanchi, 1999, Antimicrobial Agents and Chemotherapy.

Disease Eradication by Vaccination

R. Rappuoli, G. Giudice, M. Lattanzi, 2015 .

Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons

A. Izu, D. Casula, N. Groth, 2012, Human vaccines & immunotherapeutics.

Resistance Determinants and Clonal Diversity in Group A Streptococci Collected during a Period of Increasing Macrolide Resistance

G. Rossolini, S. Pollini, A. Zanchi, 2002, Antimicrobial Agents and Chemotherapy.

MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

J. Yewdell, R. Rappuoli, S. Khurana, 2011, Science Translational Medicine.

Impact of prior or concomitant seasonal influenza vaccination on MF59‐adjuvanted H1N1v vaccine (Focetria™) in adult and elderly subjects

R. Gasparini, D. Casula, M. Pellegrini, 2010, International journal of clinical practice.

The value of vaccines

R. Rappuoli, V. Masignani, M. Lattanzi, 2003, Nature Reviews Microbiology.

One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies.

R. Rappuoli, O. Finco, E. Montomoli, 2012, Vaccine.

A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP–HepB–Hib vaccine in indian infants

S. Lalwani, S. Chatterjee, M. Lattanzi, 2013, Human vaccines & immunotherapeutics.

A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.

G. D. Cioppa, G. Leroux-Roels, F. von Sonnenburg, 2012, Vaccine.

A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.

G. Leroux-Roels, F. von Sonnenburg, D. Casula, 2012, Vaccine.

Non-recent history of influenza pandemics, vaccines, and adjuvants

M. Lattanzi, 2008 .

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

W. Keitel, N. Groth, A. Hilbert, 2010, Vaccine.

Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial.

K. Edwards, I. Margarit, R. Beigi, 2020, Vaccine.

Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.

R. Bugarini, A. Podda, T. Tsai, 2009, The Journal of infectious diseases.

Associations of the correlates of protection and implication on the statistical power for demonstrating non-inferiority: application of a re-sampling method on a large phase III influenza vaccine clinical trial.

R. Bugarini, A. Podda, D. Casula, 2010, Vaccine.

Long-term solutions for the problem of vaccine shortages

R. Rappuoli, M. Lattanzi, 2004, Expert opinion on biological therapy.

MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults.

T. Mzolo, S. Block, M. Pellegrini, 2019, Vaccine.

Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial.

P. van Damme, G. Leroux-Roels, B. Corsaro, 2020, Vaccine.

A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.

R. Bugarini, A. Podda, A. Ambrozaitis, 2009, Vaccine.

Methodology of the H2 breath test. II. Importance of the test duration in the diagnosis of carbohydrate malabsorption.

G. Corazza, G. Gasbarrini, M. Lattanzi, 1990, The Italian journal of gastroenterology.

mTOR inhibition improves immune function in the elderly

J. Praestgaard, J. Kovarik, H. Maecker, 2014, Science Translational Medicine.

Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence.

F. Xie, J. Beran, M. Lattanzi, 2018, Vaccine.

Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine.

E. Reisinger, T. Jelínek, M. Alberer, 2015, Travel medicine and infectious disease.

One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.

E. Reisinger, T. Jelínek, M. Alberer, 2016, Journal of travel medicine.

Vaccination: Past, Present and Future

R. Rappuoli, M. Lattanzi, 2005 .

[Upper digestive hemorrhage in liver cirrhosis: clinical and endoscopic findings].

E. Fassio, G. Landeira, M. Lattanzi, 1992, Acta gastroenterologica Latinoamericana.

Methodology of the H2 breath test. I. Collection and storage for gas measurement.

G. Corazza, G. Gasbarrini, E. Mauriño, 1990, The Italian journal of gastroenterology.

Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.

T. Vesikari, S. Frey, A. Izu, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immunogenicity, Safety and Reactogenicity of a Mammalian Cell-Culture–Derived Influenza Vaccine in Healthy Children and Adolescents Three to Seventeen Years of Age

T. Vesikari, S. Block, A. Izu, 2012, The Pediatric infectious disease journal.

Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.

E. Kerwin, H. Watz, F. Maltais, 2022, The Lancet. Respiratory medicine.

A dose-ranging study of MF59®-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination

K. Reisinger, A. Arora, P. Pedotti, 2014, Human vaccines & immunotherapeutics.

A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults

S. Bertholet, M. Pizza, O. Finco, 2017, Human vaccines & immunotherapeutics.

Novel vaccination strategies

R. Rappuoli, M. Lattanzi, 2005, The Grand Challenge for the Future.

Fully Liquid MenACWY-CRM Vaccine: Results from an Integrated Safety Analysis

T. Mzolo, M. Pellegrini, Venere Basile, 2022, Drug Safety.

A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study.

A. Neville, G. Icardi, T. Schwarz, 2021, Vaccine.

Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults

H. Nell, T. Mzolo, Y. Kovshirina, 2021, Human vaccines & immunotherapeutics.

Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.

G. Leroux-Roels, M. Knuf, D. Kieninger-Baum, 2015, Vaccine.

Immunogenicity and Tolerability of an MF59-adjuvanted, Egg-derived, A/H1N1 Pandemic Influenza Vaccine in Children 6–35 Months of Age

G. Leroux-Roels, M. Knuf, D. Kieninger-Baum, 2014, The Pediatric infectious disease journal.

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.

K. Matsushita, H. Yotsuyanagi, H. Fukase, 2012, Vaccine.

Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children

K. Matsushita, M. Lattanzi, R. Komatsu, 2010, Advances in therapy.

Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.

T. Vesikari, S. Frey, A. Izu, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

J. Yewdell, R. Rappuoli, S. Khurana, 2011, Science Translational Medicine.

Meningitis C vaccine (North American vaccine).

G. Del Giudice, M. Lattanzi, 2002, Current opinion in investigational drugs.